Department of Digestive and Oncological Surgery, Centre Hospitalier Regional Universitaire, University Hospital C. Huriez, Place de Verdun, 59037 Lille Cedex, France.
Eur J Surg Oncol. 2012 Mar;38(3):210-3. doi: 10.1016/j.ejso.2011.12.022. Epub 2012 Jan 10.
Oesophagectomy for carcinoma can be viewed as comprising two components: resection of the oesophagus and resection of the enveloping lymphatics. Controversy exists regarding how extensive these two components should be.
Through a literature overview, the aim of this educational article is to provide surgeons with arguments to understand which operation is the most oncologically sound according to patient and tumour parameters.
Non-randomised comparative studies evaluating radical lymphadenectomy have reported controversial survival benefit. Independent association found between the number of surgically removed lymph nodes and overall survival is an indirect evidence supporting radical lymphadenectomy. The only phase III trial comparing non-radical transhiatal oesophagectomy with transthoracic oesophagectomy for patients with oesophageal adenocarcinoma found 5-year survival rates of 29% vs. 39%, respectively. Although not statistically significant due to underpowered study, specialists would consider less of an increase in survival to be clinically relevant. For squamous OC, the first small randomised controlled trial comparing 2-field lymphadenectomy to 3-field lymphadenectomy did not found significant 5-year survival difference (48% vs. 66%) and the second one comparing 2-field lymphadenectomy to lymph node sampling identified a survival benefit favoring radical resection (36% vs. 25%).
Radical transthoracic oesophagectomy with two-field lymphadenectomy appears to offer an optimal balance between benefits and risks to a majority of OC patients, especially in the growing area of neoadjuvant treatments. Non-radical resection should be probably reserved for patients with a poor general status whereas 3-field lymphadenectomy may be reserved to selected patients with loco-regional disease in experienced hands, surely for patients with upper OC.
食管癌切除术可分为两部分:食管切除术和包裹性淋巴切除术。这两部分的范围应该有多大,存在争议。
通过文献综述,本文旨在为外科医生提供一些论据,以了解根据患者和肿瘤参数,哪种手术在肿瘤学上更为合理。
评价根治性淋巴结清扫术的非随机对照研究报告了有争议的生存获益。手术切除的淋巴结数量与总生存率之间存在独立关联,这是支持根治性淋巴结清扫术的间接证据。唯一一项比较非根治性经胸食管切除术与经胸食管切除术治疗食管腺癌患者的 III 期试验发现,5 年生存率分别为 29%和 39%。尽管由于研究力量不足,统计学上无显著差异,但专家们认为,生存率的适度增加在临床上是相关的。对于鳞状 OC,第一项比较 2 野淋巴结清扫与 3 野淋巴结清扫的小型随机对照试验未发现 5 年生存率有显著差异(48%与 66%),第二项比较 2 野淋巴结清扫与淋巴结取样的试验发现,根治性切除有生存获益(36%与 25%)。
对于大多数 OC 患者,尤其是在新辅助治疗不断发展的情况下,根治性经胸食管切除术和 2 野淋巴结清扫术似乎在获益和风险之间达到了最佳平衡。非根治性切除术可能应保留给一般状况较差的患者,而 3 野淋巴结清扫术可能应保留给在经验丰富的医生手中局部区域疾病的选定患者,特别是对于上 OC 患者。